CNTO-530
CNTO-530 is a biopharmaceutical agent developed for the treatment of anemia, particularly in patients with chronic kidney disease (CKD). It is a type of erythropoiesis-stimulating agent (ESA) designed to stimulate the production of red blood cells by mimicking the action of erythropoietin, a hormone naturally produced by the kidneys.
Mechanism of Action[edit | edit source]
CNTO-530 functions by binding to and activating the erythropoietin receptor on the surface of erythroid progenitor cells in the bone marrow. This activation leads to the proliferation and differentiation of these progenitor cells into mature red blood cells, thereby increasing the red blood cell count and improving oxygen delivery to tissues.
Development and Clinical Trials[edit | edit source]
CNTO-530 was developed by Janssen Biotech, a subsidiary of Johnson & Johnson. It underwent several phases of clinical trials to evaluate its safety, efficacy, and optimal dosing regimens. The trials primarily focused on patients with anemia due to chronic kidney disease, a condition where the kidneys fail to produce adequate amounts of erythropoietin.
Potential Benefits[edit | edit source]
The use of CNTO-530 in treating anemia associated with CKD offers several potential benefits:
- Reduced Need for Blood Transfusions: By stimulating endogenous red blood cell production, CNTO-530 can reduce the need for blood transfusions, which carry risks such as iron overload and transfusion reactions.
- Improved Quality of Life: Anemia can cause symptoms such as fatigue, weakness, and shortness of breath. By alleviating these symptoms, CNTO-530 can improve the quality of life for patients.
Safety and Side Effects[edit | edit source]
As with other erythropoiesis-stimulating agents, CNTO-530 may have side effects, including:
- Hypertension: Increased blood pressure is a common side effect due to the increased red blood cell mass.
- Thromboembolic Events: There is a risk of blood clots, which can lead to serious complications such as stroke or myocardial infarction.
Regulatory Status[edit | edit source]
As of the latest updates, CNTO-530 has not been approved for general clinical use and remains under investigation. The regulatory status may vary by region and is subject to change based on ongoing research and clinical trial outcomes.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
